Among biologic-naive patients with psoriatic arthritis, 58% who received icotrokinra (ICOTYDE) hit an ACR20 response at Week 16, against 41% on placebo, in the Phase 3 ICONIC-PsA 1 trial. That 17-percentage-point gap, presented as a late-breaking poster at ACR Convergence 2026, is the first Phase 3 readout for icotrokinra specifically in PsA, and it matters because approved IL-23 pathway agents in PsA have so far worked by blocking the cytokine itself rather than its receptor.
The skin numbers from ICONIC-PsA 1 sharpen the picture. Among patients with qualifying baseline skin involvement, 57% receiving icotrokinra achieved clear or almost clear skin (IGA 0/1) versus 14% on placebo, and 37% hit PASI 90 versus 6%. ACR50 came in at 29% versus 16%. Crucially, response rates kept climbing through Week 24, without a randomized comparator arm at that stage since placebo patients crossed over at Week 16, reaching 69% ACR20, 56% PASI 90, and 64% IGA 0/1. That trajectory matters for a disease where durable joint and skin control is the practical clinical question.
The mechanism here is distinct enough to notice. Guselkumab and risankizumab block IL-23 the cytokine; icotrokinra blocks the IL-23 receptor itself, which J&J describes as the first and only targeted oral peptide with that mechanism. It already holds FDA approval for moderate-to-severe plaque psoriasis. The PsA program runs a parallel Phase 3, ICONIC-PsA 2, that includes both biologic-naive and biologic-experienced patients, so the ICONIC-PsA 1 readout covers only one slice of the population regulators will want to see characterized. No safety signals beyond the established profile appeared through Week 24, though the crossover design limits long-term placebo-controlled safety inference.
The number to watch from here is the ICONIC-PsA 2 readout, which will determine whether the ACR20 signal holds in patients who have already failed a biologic, the population that tends to be harder to move and whose response rate will shape the drug’s eventual position in treatment sequencing.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
